Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Scientists discover new potential target for treating non-Hodgkin's lymphoma

Scientists discover new potential target for treating non-Hodgkin's lymphoma

Discovery holds promise in fighting cancer, AIDS and autoimmune disorders

Discovery holds promise in fighting cancer, AIDS and autoimmune disorders

Prolonged exposure to formaldehyde linked with increased risk of myeloid leukemia

Prolonged exposure to formaldehyde linked with increased risk of myeloid leukemia

SCF founder Sabrina Cohen recognized as a WebMD 2009 Health Hero

SCF founder Sabrina Cohen recognized as a WebMD 2009 Health Hero

Scientists closer to unraveling the mechanisms of gene regulation

Scientists closer to unraveling the mechanisms of gene regulation

Aegera Therapeutics commences AEG35156 Phase 2B study for AML

Aegera Therapeutics commences AEG35156 Phase 2B study for AML

Genetic identity of cellular receptor for the immune system's first-response antibody discovered

Genetic identity of cellular receptor for the immune system's first-response antibody discovered

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

CytRx plans Phase 2 clinical trial of its doxorubicin prodrug for advanced gastric cancer

CytRx plans Phase 2 clinical trial of its doxorubicin prodrug for advanced gastric cancer

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Asuragen enters into an exclusive agreement with Life Technologies

Asuragen enters into an exclusive agreement with Life Technologies

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

Cord Blood reports its 10Q filing with the U.S. SEC for the three and nine-month period ended September 30, 2009

Cord Blood reports its 10Q filing with the U.S. SEC for the three and nine-month period ended September 30, 2009

Fate Therapeutics announces the completion of $30 million Series B financing

Fate Therapeutics announces the completion of $30 million Series B financing

EntreMed announces financial results for the third quarter of 2009

EntreMed announces financial results for the third quarter of 2009

Two units of UCB reduce risk of leukemia from returning, shows new study

Two units of UCB reduce risk of leukemia from returning, shows new study

Researchers find a new way to tackle colon cancer

Researchers find a new way to tackle colon cancer

Trubion Pharmaceuticals to present data on its TRU-016 product candidate at the ASH meeting

Trubion Pharmaceuticals to present data on its TRU-016 product candidate at the ASH meeting

Stapled Peptides directly inhibit the Notch transcription factor complex

Stapled Peptides directly inhibit the Notch transcription factor complex

Stapled Peptides can inhibit key intracellular biological targets, says new research

Stapled Peptides can inhibit key intracellular biological targets, says new research

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.